Basic Information
| LncRNA/CircRNA Name | SNHG22 |
| Synonyms | NA |
| Region | GRCh38_18:49814023-49851059 |
| Ensemble | ENSG00000267322 |
| Refseq | NR_117096 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Paclitaxel | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | epithelial ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qRT-PCR , Luciferase reporter assay , Western blot , RIP , in vitro knockdown etc. |
| Sample | human normal ovarian and EOC tissues ,EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP) |
| Expression Pattern | up-regulated |
| Function Description | SNHG22 was significantly increased in EOC tissues and was significantly associated with a low level of differentiation. Forced SNHG22 expression promoted chemotherapy resistance in EOC cells.Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel.Importantly, SNHG22 could directly interact with miR-2467 and lead to the release of miR-2467-targeted Gal-1 mRNA. Moreover, SNHG22 overexpression induced EOC cell resistance to chemotherapy agents via PI3K/AKT and ERK cascade activation. |
| Pubmed ID | 31581131 |
| Year | 2019 |
| Title | SNHG22 Overexpression Indicates Poor Prognosis and Induces Chemotherapy Resistance via the miR-2467/Gal-1 Signaling Pathway in Epithelial Ovarian Carcinoma |
External Links
| Links for SNHG22 | GenBank HGNC NONCODE |
| Links for epithelial ovarian cancer | OMIM COSMIC |